VA GLA Pluvicto and Lutathera

Read the official notice on SAM.gov

Summary from the notice

NOTICE OF INTENT TO SOLE SOURCE This notice is being published in accordance with Federal Acquisition Regulation (FAR) Subpart 5.101 requiring dissemination of information for proposed contract actions. This is a notice of intent to award a sole source contract and is not a request for competitive quotes/proposals. The Department of Veterans Affairs, Network Contracting Office (NCO) 22, located at 4811 Airport Plaza Drive, Long Beach, CA is issuing this Notice of Intent (NOI) to inform industry contractors of the Government s intent to execute a Sole Source Delivery Order under FAR Part 8, specifically FAR Part 8.405-6(a)(1)(B), Only One Available Source. The North American Industry Classification System (NAICS) for this requirement is 325412, Pharmaceutical Preparation Manufacturing. The Federal Supply Class (FSC) is 6505, Drugs and Biologicals. The Small Business Administration (SBA) size standard for this sector is 1,300 Employees. The intended contractor is Novartis Pharmaceuticals Corporation located at 59 Route 10, East Handover, NJ 07936. Place of Performance is the VA Greater Los Angeles Healthcare System located at 11301 Wilshire Blvd, Los Angeles, CA 90073. VA Greater Los Angeles Nuclear Medicine Service intends to purchase Pluvicto (lutetium Lu-177 vipivotide tetraxetan 27 mCi/mL) and Lutathera (lutetium LU 177 Dotatate) in quantities listed below: NDC# Contract Description Qty UOM 00078-1217-61 36F79720D0180 Pluvicto (lutetium Lu-177 vipivotide tetraxetan 27 mCi/m…

Other open NAICS 325412 notices